Relmada Therapeutics Inc [RLMD] stock is trading at $0.38, up 11.73%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RLMD shares have gain 4.17% over the last week, with a monthly amount drifted -19.17%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Relmada Therapeutics Inc [NASDAQ: RLMD] stock has seen the most recent analyst activity on December 05, 2024, when Mizuho downgraded its rating to a Neutral and also revised its price target to $1 from $23. Previously, Jefferies upgraded its rating to Buy on September 17, 2024, and elevated its price target to $13. On June 05, 2024, downgrade downgraded it’s rating to Sell and revised its price target to $2 on the stock. Truist downgraded its rating to a Hold and decreased its price target to $10 on October 14, 2022. Guggenheim downgraded its rating to a Neutral. Goldman downgraded its rating to Neutral for this stock on October 14, 2022, and downed its price target to $8. In a note dated October 13, 2022, Oppenheimer downgraded an Perform rating on this stock and revised its target price from $64 to $7.
Relmada Therapeutics Inc [RLMD] stock has fluctuated between $0.31 and $7.22 over the past year. Currently, Wall Street analysts expect the stock to reach $5.67 within the next 12 months. Relmada Therapeutics Inc [NASDAQ: RLMD] shares were valued at $0.38 at the most recent close of the market. An investor can expect a potential return of 1392.11% based on the average RLMD price forecast.
Analyzing the RLMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.55, Equity is -1.3 and Total Capital is -1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3387 points at the first support level, and at 0.2975 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4071, and for the 2nd resistance point, it is at 0.4343.
Ratios To Look Out For
For context, Relmada Therapeutics Inc’s Current Ratio is 6.89. Further, the Quick Ratio stands at 6.89, while the Cash Ratio is 0.18.
Transactions by insiders
Recent insider trading involved TRAVERSA SERGIO, Chief Executive Officer, that happened on Sep 11 ’24 when 51407.0 shares were purchased. Chief Executive Officer, TRAVERSA SERGIO completed a deal on Sep 09 ’24 to buy 55579.0 shares. Meanwhile, Chief Executive Officer TRAVERSA SERGIO bought 33014.0 shares on Sep 10 ’24.
